IRIS
MARRONE, Aldo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.910
NA - Nord America 6.778
AS - Asia 5.556
SA - Sud America 874
AF - Africa 62
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 2
Totale 26.188
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 8.306
US - Stati Uniti d'America 6.640
SG - Singapore 1.988
IE - Irlanda 1.365
CN - Cina 1.229
HK - Hong Kong 754
VN - Vietnam 748
BR - Brasile 734
UA - Ucraina 695
IT - Italia 671
GB - Regno Unito 601
DE - Germania 447
SE - Svezia 242
KR - Corea 206
TR - Turchia 196
FI - Finlandia 194
IN - India 139
JP - Giappone 133
GR - Grecia 127
FR - Francia 89
CA - Canada 81
AR - Argentina 56
NL - Olanda 36
BD - Bangladesh 35
AT - Austria 30
MX - Messico 30
BE - Belgio 26
ID - Indonesia 23
EC - Ecuador 19
IQ - Iraq 19
CO - Colombia 18
PL - Polonia 18
ES - Italia 16
ZA - Sudafrica 16
VE - Venezuela 13
CZ - Repubblica Ceca 12
MA - Marocco 11
CL - Cile 10
EG - Egitto 10
PE - Perù 10
IR - Iran 9
UZ - Uzbekistan 9
CH - Svizzera 7
HN - Honduras 7
PH - Filippine 7
PY - Paraguay 7
AE - Emirati Arabi Uniti 6
EU - Europa 6
PK - Pakistan 6
AZ - Azerbaigian 5
JM - Giamaica 5
KE - Kenya 5
RO - Romania 5
TH - Thailandia 5
UY - Uruguay 5
DZ - Algeria 4
ET - Etiopia 4
HR - Croazia 4
MY - Malesia 4
NP - Nepal 4
TN - Tunisia 4
TW - Taiwan 4
AL - Albania 3
AM - Armenia 3
BG - Bulgaria 3
HU - Ungheria 3
JO - Giordania 3
LT - Lituania 3
PA - Panama 3
PS - Palestinian Territory 3
SN - Senegal 3
TT - Trinidad e Tobago 3
CR - Costa Rica 2
CY - Cipro 2
GE - Georgia 2
LK - Sri Lanka 2
NI - Nicaragua 2
OM - Oman 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
UG - Uganda 2
AU - Australia 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
MK - Macedonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
Totale 26.183
Salva come PNG Salva come JPEG
Città #
Moscow 2.927
Dublin 1.359
Jacksonville 1.049
Singapore 864
Hong Kong 739
Santa Clara 735
Chandler 714
San Jose 619
Ashburn 299
New York 287
Ho Chi Minh City 232
Princeton 210
Seoul 200
Hanoi 184
Roxbury 158
Woodbridge 139
Beijing 133
Hefei 130
Ann Arbor 126
The Dalles 124
Boardman 121
Cambridge 116
Bremen 110
Wilmington 104
Dallas 101
Medford 101
Bengaluru 76
Munich 76
Naples 71
Caserta 64
Da Nang 60
Jinan 60
Los Angeles 60
São Paulo 58
San Mateo 53
Shenyang 52
Nanjing 50
Des Moines 45
Orem 43
Mountain View 41
Düsseldorf 33
Haiphong 33
Memphis 33
Zhengzhou 31
Brussels 26
Guangzhou 26
Nanchang 25
Hangzhou 24
Rio de Janeiro 23
Amsterdam 22
Houston 22
Milan 22
Napoli 22
Frankfurt am Main 21
Washington 21
Changsha 20
Helsinki 20
Montreal 20
Atlanta 19
Chennai 19
Norwalk 19
Haikou 18
Nuremberg 18
Tianjin 18
Brasília 17
Shanghai 17
Thái Nguyên 17
London 16
Hebei 15
Ningbo 15
Ottawa 15
Rome 15
Belo Horizonte 14
Biên Hòa 14
Lanzhou 14
Taiyuan 14
Tokyo 14
Toronto 14
Warsaw 14
Auburn Hills 13
Seattle 13
Vienna 13
Council Bluffs 12
Taizhou 12
Kunming 11
Turku 11
Campinas 10
Curitiba 10
Hải Dương 10
Jiaxing 10
Sorocaba 10
Can Tho 9
Chicago 9
Istanbul 9
Padova 9
Dearborn 8
Guayaquil 8
Ha Long 8
Marano Di Napoli 8
Ninh Bình 8
Totale 13.681
Salva come PNG Salva come JPEG
Nome #
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C 206
Cannabinoid receptor 2-63 QQ varianti s associated with severe necroinflammation in chronic epatiti C 205
Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: Effects of hepatitis B virus co-infection and interferon treatment 191
Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. 191
Mechanisms and clinical behavior of hepatocellular carcinoma in HBV and HCV infection and alcoholic and non-alcoholic fatty liver disease 189
Non-invasive respiratory support in SARS-CoV-2 related acute respiratory distress syndrome: when is it most appropriate to start treatment? 182
Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C 181
Cannabinoid Receptor 2 (CB2) Q63 variant in chronic hepatitis C: an association with a more severe hepatocellular necrosis. 176
Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration 175
Activity of aminoglycosides against phagocytosed bacteria 171
Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms 170
CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. 170
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort 166
Predictors of in-hospital mortality of COVID-19 patients and the role of telemetry in an internal medicine ward during the third phase of the pandemic 166
Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology? 165
Chronic HCV infection and neurological and psychiatric disorders: an overview. 164
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe. 162
IMPACT OF TYPE II DIABETES ON HCC APPEARANCE IN PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 162
COVID-19 and arrhythmia: The factors associated and the role of myocardial electrical impulse propagation. An observational study based on cardiac telemetric monitoring 161
Cannabinoid receptor 2 (CB2) Q63 variant is associated with a severe histological activity index in patients with chronic hepatitis C 161
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study 159
HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis 158
Absence of hepatitis C viral infection among patients with primary Sjogren's syndrome 158
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe 158
Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy 158
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 157
Predictors of early and late hepatocellular carcinoma recurrence 155
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. 155
Mortality and risk factors of vaccinated and unvaccinated COVID-19 frail patients treated with anti-SARS-CoV-2 monoclonal antibodies. A real-world study 154
Chronic hepatitis B infection in pediatric patients cured of oncologic diseases: natural history and effect of interferon treatment 152
Atherosclerosis and chronic hepatitis C virus (HCV) infection: Role of liver steatosis 152
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19 152
Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: a multicenter prospective study 151
The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B. 149
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study 149
Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study 149
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management 148
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. 147
Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection 145
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 141
Clinical application of lung ultrasound score on COVID-19 setting: a regional experience in Southern Italy 141
Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? 139
Long-Term Prognosis among COVID-19 Patients: The Predictive Role Played by Hyperinflammation and Arrhythmic Disorders in Fatal Outcome 139
Prediction of SARS-CoV-2-Related Lung Inflammation Spreading by V:ERITAS (Vanvitelli Early Recognition of Inflamed Thoracic Areas Spreading) 138
Authors’ response 137
A hyper-glycosilation of HBV surface major hydrophilic correlates with immunosuppression-driven HBV reactivation and hampers HBsAg recognition in vitro 136
Hepatic steatosis and necro-inflammatory activity overestimated liver stiffness by transient elastography in staging liver fibrosis in chronic hepatitis C 135
A hyper-glycosilation of HBV surface major hydrophilic region characterizes HBV reactivation driven by immunosuppression and affects HBsAg recognition in vitro 135
A Case Report on Treatment of Nonhealing Leg Ulcer: Do Not Forget the Underlying Disease 135
Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma 134
PNPLA3 l148M variant as a risk factor for carotid atherosclerosis in chronic epatiti C 134
Aspetti diagnostici di mutanti della regione HBsAg in pazienti immunocompromessi con riattivazione dell’infezione da virus dell’epatite B (HBV). 133
Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals 133
Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B 132
Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study 131
Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination 130
Ruolo patogenetico dell'adiponectina nella steatosi associata ad epatite C 130
Effect of prednisone priming followed by alpha-interferon in treatment of children with chronic hepatitis B: an interim analysis of a controlled trial 129
Treatment of chronic hepatitis B in children with prednisone followed by alpha-interferon: a controlled randomized study 129
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection 129
La epatite cronica da HCV con steatosi si associa ad elevato rischio aterosclerotico. 128
Baseline HBV-DNA level is an important predictor of response to interferon in children with chronic hepatitis B 128
EFFICACIA DEL TRATTAMENTO CON INTERFERONE RICOMBINANTE E LINFOBLASTOIDE IN PAZIENTI CON EPATITE CRONICA DA HCV 128
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 127
Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection 126
Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients 126
Esperienza con l'interferone linfoblastoide nelle epatiti croniche virali 126
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B. 126
Liver Involvement during SARS-CoV-2 Infection Is Associated with a Worse Respiratory Outcome in COVID-19 Patients 125
Immunocompromised patients with HBsAg a determinant mutants: comparison of HBsAg diagnostic assays 125
HCV-related steatosis and risk of atherosclerosis 125
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 124
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 124
Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals 124
Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. 123
Espressione dell'infezione da citomegalovirus (CMV) in pazienti cardiotrapiantati 122
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. 122
Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B 122
Interferon-induced anti-HBE seroconversion correlates with a Th1 cytokine shift following emergence of core promoter mutations in chronic hepatitis B 121
Viral Hepatitis C 120
Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon 119
Ricerca del sangue occulto nelle feci con Hemoquant: prevenzione e diagnostica. 119
Le complicanze infettive in pazienti sottoposti a trapianto di cuore: dati del centro napoletano. 119
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore. 119
Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C 118
The TM6SFZ 8167K variant is an independent predictor of severe liver steatosis in chronic hepatitis C 118
Ruolo patogenetico dell’adiponectina nella steatosi associata ad epatite C 117
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. 117
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 116
Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission 116
Tm6sf2 e167k variant is associated with severe steatosis in chronic hepatitis c, regardless of pnapl3 polymorphism 116
Long term effect of interferon (IFN) treatment of chronic hepatitis B (CHB) in pediatric patients cured of oncologic diseases 116
Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study 115
ESPERIENZA CON L'INTERFERONE LINFOBLASTOIDE NELLE EPATITI CRONICHE VIRALI 115
Efficacia e sicurezza dell’entecavir nel controllo dell’infezione da HBV nel paziente oncoematologico 115
PNPLA3 I148M variant is associated with liver steatosis and fat distribution in chronic hepatitis B 115
Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals 114
Pleurite da Listeria monocytogenes in un paziente con cirrosi epatica: osservazione di un caso clinico 114
Treatment of chronic hepatitis B: efficacy of current drugs and prospects for the future 114
Different serological, molecular and cytokine profiles characterize active and inactive disease in patients with chronic hepatitis B virus (HBV) infection 114
Totale 14.058
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.754
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.754
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202167 0 0 0 0 0 0 0 0 0 0 0 67
2021/20221.284 59 3 8 15 435 14 11 35 64 124 102 414
2022/20232.682 235 45 38 216 326 221 4 174 1.276 27 64 56
2023/20241.207 95 33 61 97 372 262 17 34 4 14 77 141
2024/20253.161 27 42 33 87 502 357 391 274 436 487 277 248
2025/202613.847 488 593 682 675 1.093 7.778 827 542 525 279 246 119
Totale 26.590